This company has been acquired
ABMD Stock Overview
Abiomed, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 1/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Abiomed, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$381.02 |
| 52 Week High | US$381.99 |
| 52 Week Low | US$219.85 |
| Beta | 1.4 |
| 1 Month Change | 0.86% |
| 3 Month Change | 55.18% |
| 1 Year Change | 8.18% |
| 3 Year Change | 125.10% |
| 5 Year Change | 103.31% |
| Change since IPO | 6,385.45% |
Recent News & Updates
Recent updates
Abiomed's Impella low profile sheath gets FDA clearance
Oct 17Abiomed: Correction Offers Good Buying Opportunity
Sep 28U.S. FDA gives two approvals to Abiomed Impella heart pumps
Sep 16Abiomed FQ1 2023 Earnings Preview
Aug 03Abiomed's Profit Growth Slows On R&D, Sales Hold Strong Despite Shortages
May 17Abiomed's Less Troubled 2020 Justifies Multiple, But Medium-Term Headwinds Mean Capital Risk
Jan 24Abiomed: Impella Will Continue To Drive Revenue Growth
Sep 10Abiomed: Recovery Mode Has Been Activated - Reiterate Buy Rating
Jul 13DSMB recommends Abiomed trial for heart pump in cardiogenic shock continue
Jun 08Abiomed acquires preCARDIA a company targeting acute heart failure
Jun 01Boston Scientific’s new clinical trial can impact Abiomed: Raymond James
May 06Abiomed FQ4 2021 Earnings Preview
Apr 28Shareholder Returns
| ABMD | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 0.005% | 0.8% | 0.6% |
| 1Y | 8.2% | 10.0% | 23.8% |
Return vs Industry: ABMD exceeded the US Medical Equipment industry which returned -23.7% over the past year.
Return vs Market: ABMD exceeded the US Market which returned -22.8% over the past year.
Price Volatility
| ABMD volatility | |
|---|---|
| ABMD Average Weekly Movement | 14.6% |
| Medical Equipment Industry Average Movement | 8.0% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 17.6% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: ABMD's share price has been volatile over the past 3 months.
Volatility Over Time: ABMD's weekly volatility has increased from 9% to 15% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1981 | 2,003 | Mike Minogue | www.abiomed.com |
Abiomed, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides a continuum of care to heart failure patients. The company offers Impella 2.5, a percutaneous micro heart pump with integrated motor and sensors; and Impella CP, a device for use by interventional cardiologists to support patients in the cath lab, as well as by cardiac surgeons in the heart surgery suite.
Abiomed, Inc. Fundamentals Summary
| ABMD fundamental statistics | |
|---|---|
| Market cap | US$17.19b |
| Earnings (TTM) | US$266.76m |
| Revenue (TTM) | US$1.07b |
64.4x
P/E Ratio16.0x
P/S RatioIs ABMD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ABMD income statement (TTM) | |
|---|---|
| Revenue | US$1.07b |
| Cost of Revenue | US$200.59m |
| Gross Profit | US$873.51m |
| Other Expenses | US$606.74m |
| Earnings | US$266.76m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | 5.91 |
| Gross Margin | 81.32% |
| Net Profit Margin | 24.84% |
| Debt/Equity Ratio | 0% |
How did ABMD perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2022/12/24 09:15 |
| End of Day Share Price | 2022/12/21 00:00 |
| Earnings | 2022/09/30 |
| Annual Earnings | 2022/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Abiomed, Inc. is covered by 26 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Lawrence Neibor | Baird |
| Jan Wald | Benchmark Company |
| Michael Gorman | BTIG |